Sign in

CIK 0001885522

  • Non-accelerated filer
  • Smaller reporting company

Neumora Therapeutics, Inc.

Sign in to watch
Ticker
NMRA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
844367680
Phone
+1 857-760-0900
Business address
260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
  1. 4 Open-market buy Director bought 140,605 shares at an average $10.98 ($1,543,563)
  2. 4 Open-market buy 10% owner bought 140,605 shares at an average $10.98 ($1,543,563)
  3. 4 Open-market buy Director bought 95,694 shares at an average $11.49 ($1,099,945)
  4. 4 Open-market buy 10% owner bought 95,694 shares at an average $11.49 ($1,099,945)
  5. 4 Open-market buy Director bought 76,511 shares at an average $13.68 ($1,046,848)
  6. 4 Open-market buy 10% owner bought 76,511 shares at an average $13.68 ($1,046,848)
  7. 4 Open-market buy Director bought 58,504 shares at an average $11.97 ($700,464)
  8. 4 Open-market buy 10% owner bought 58,504 shares at an average $11.97 ($700,464)
  9. 4 Open-market buy 10% owner bought 100,740 shares at an average $11.19 ($1,127,064)
  10. 4 Open-market buy Director bought 100,740 shares at an average $11.19 ($1,127,064)
  11. 4 Conversion FMR LLC acquired 3,712,624 shares (conversion)
  12. 4 Open-market buy Director bought 1,500,000 shares at $17.00 ($25,500,000)
  13. 4 Open-market buy 10% owner bought 1,500,000 shares at $17.00 ($25,500,000)
  14. 4 Open-market buy 10% owner bought 1,500,000 shares at $17.00 ($25,500,000)
  15. 4 Open-market buy President & CEO bought 15,000 shares at $12.62 ($189,371)
  16. 4 Open-market buy 10% owner bought 1,764,705 shares at $17.00 ($29,999,985)
  17. 4 Grant or award Head of R&D acquired 352,941 shares (grant or award)
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 5 of 6 · 118 filings